

Page 4, line 12, replace "labelled" with -labeled-;

Page 4, line 13, after "(AHWSGHCCL)", insert -SEQ ID NO: 1-;

Page 4, line 17, insert a comma after "of";

Page 4, line 18, insert a comma after "respectively";

Page 4, line 19, replace "labelled" with -labeled-;

Page 4, lines 22-23, replace "of reducing" with -to reduce-;

Page 4, line 25, replace "labelled" with -labeled-;

Page 4, line 27, replace "labelled" with -labeled-;

Page 4, line 28, replace "In cases like this it" with -It-;

Page 4, line 29, replace "occurs" with -occur-;

Page 4, line 32, replace "It goes without saying that the" with -The-;

Page 5, lines 13-14, replace "Applicant considers the possibility that migraine is also"

with -Migraines may also be-;

Page 5, line 16, replace "an advantageous" with -a preferred-;

Page 8, line 4, replace "foetal" with -fetal-;

Page 8, line 5, replace "FTIC-labelled" with -FITC-labeled-;

Page 8, line 11, replace "unlabelled" with -unlabeled-;

Page 8, line 20, replace "min." with -minutes-;

Page 10, line 21, replace "sensitisation" with -sensitization-; and

Page 12, line 11, replace "Fig." with -FIG.-.

IN THE CLAIMS:

3. (Amended) The compound of claim 1 [or 2], wherein the compound reduces the binding between the peptide and the free light chain of immunoglobulin by at least 10%[, preferably by at least 25%, more preferably by at least 50%, even more preferably by at least 75%, and most preferably by 90%].

4. (Amended) The compound of claim 2 [or 3], wherein the compound is a peptidomimeticum.